The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children.
The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children.
复制标题
DOI：
10.1016/j.jaci.2010.05.026
复制
发表时间：
2010-08
期刊：
影响因子：
--
通讯作者：
Palivizumab Long-Term Respiratory Outcomes Study Group
中科院分区：
文献类型：
--
作者：
Simões EA;Carbonell-Estrany X;Rieger CH;Mitchell I;Fredrick L;Groothuis JR;Palivizumab Long-Term Respiratory Outcomes Study Group
虽然早期呼吸道合胞病毒(RSV)感染下呼吸道感染(LRTI)会导致晚期呼吸道高反应性，但目前尚不清楚这与特应性素质之间是否存在因果关系。为了区分呼吸道合胞病毒LRTI和特应性素质对随后再发喘息的影响，我们研究了在有和没有特应性家族史的婴儿中，先前使用palivizumab对随后再发喘息的保护作用。在欧洲和加拿大的27个中心进行了一项前瞻性的多中心、配对、双队列研究。在出生第一年接受帕利维珠单抗治疗的早产儿和妊娠36周的早产儿中，医生诊断的反复喘息的发生率与胎龄匹配的对照组进行了比较。在那些没有哮喘家族史的人中，帕利维珠单抗对医生诊断的2~5岁反复喘息的相对保护作用为68%(优势比为0.32；(95%CI，0.14-0.75；N=146，未治疗)；在没有特应性或食物过敏家族史的人中，Palivizumab的相对保护效果为80%(优势比，0.20；95%CI，0.07-0.59；N=101，Palivizumab，100未治疗)。相比之下，在90名有特应性家族史或食物过敏的儿童中，与130名有特应性家族史的未经治疗的婴儿相比，帕利维珠单抗对随后的反复喘息没有影响。在非特应性儿童中预防呼吸道合胞病毒可以降低80%反复喘息的相对风险，但对有特应性家族史的婴儿没有任何影响。这表明RSV在一种特应性非特应性机制中易于反复喘息。
Although respiratory syncytial virus (RSV) lower respiratory tract infections (LRTIs) in early life are followed by later airway hyperreactivity, it is unclear whether there is a causal relationship between this and an atopic diathesis. To separate the effects of RSV LRTI and an atopic diathesis on subsequent recurrent wheezing, we examined the protective effect of previous palivizumab administration against subsequent recurrent wheeze in infants with and without a family history of atopy. A prospective multicenter, matched, double cohort study was conducted in 27 centers in Europe and Canada. The rates of physician-diagnosed recurrent wheezing in premature infants <36 weeks gestation who had received palivizumab in the first year of life were compared to those of gestational age–matched controls. The relative protective effect of palivizumab on physician-diagnosed recurrent wheezing through the ages of 2 to 5 years was 68% in those with no family history of asthma (odds ratio, 0.32; (95% CI, 0.14-0.75; N = 146 palivizumab-treated, 171 untreated) and 80% in those with no family history of atopy or food allergies (odds ratio, 0.20; 95% CI, 0.07-0.59; N = 101 palivizumab-treated, 100 untreated). In contrast, there was no effect of palivizumab on subsequent recurrent wheezing in the 90 children with a family history of atopy or food allergies compared to 130 untreated infants with atopic families. Respiratory syncytial virus prophylaxis in nonatopic children decreases by 80% the relative risk of recurrent wheezing but does not have any effect in infants with an atopic family history. This suggests that RSV predisposes to recurrent wheezing in an atopy-independent mechanism.
登录
查看更多内容
影响因子：
168.9
作者：
Stern, Debra A.;Morgan, Wayne J.;Halonen, Marilyn;Wright, Anne L.;Martinez, Fernando D.
通讯作者：
Martinez, Fernando D.
DOI：
10.1164/ajrccm.161.5.9906076
发表时间：
2000-05-01
影响因子：
24.7
作者：
Sigurs, N;Bjarnason, R;Kjellman, B
通讯作者：
Kjellman, B
影响因子：
5.9
作者：
Wenzel, SE;Gibbs, RL;Simoes, EAF
通讯作者：
Simoes, EAF
影响因子：
168.9
作者：
Stein, R;Sherrill, D;Martinez, FD
通讯作者：
Martinez, FD
DOI：
10.1016/j.jaci.2006.12.669
发表时间：
2007-05
期刊：
The Journal of allergy and clinical immunology
影响因子：
--
作者：
Kusel MM;de Klerk NH;Kebadze T;Vohma V;Holt PG;Johnston SL;Sly PD
通讯作者：
Sly PD